GlassScriptPhysician profile
Deena Kapadia
NPI 1326535691
$3,069.76
in general payments reported to CMS, 2019-2025
17 companies · $1,856 in 2025
The $1,856 reported for 2025 was more than what 93% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $11.23 · 2021: $19.36 · 2023: $323 · 2024: $860 · 2025: $1,856.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,039.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,039.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $729.76 | 2023-2025 | Xifaxan |
| Gilead Sciences, INC. | $575.22 | 2024-2025 | |
| Madrigal Pharmaceuticals | $481.12 | 2024-2025 | Rezdiffra, Resmetirom |
| Mallinckrodt Hospital Products INC. | $328.05 | 2023-2024 | Terlivaz |
| Ipsen Biopharmaceuticals, INC | $202.98 | 2024-2025 | Iqirvo |
| Abbvie INC. | $202.86 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $120.03 | 2024-2025 | Livtencity |
| Veloxis Pharmaceuticals, INC. | $111.59 | 2024-2025 | Envarsus |
| Fujifilm Healthcare Americas Corporation | $95.33 | 2025 | |
| Sanofi-Aventis U.S. LLC | $46.28 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $41.76 | 2023 | Lokelma |
| Merck Sharp & Dohme LLC | $41.25 | 2024-2025 | Prevymis, Dificid |
| Orphalan INC | $27.00 | 2023 | Cuvrior |
| Csl Behring | $19.36 | 2021 | |
| Mirum Pharmaceuticals, INC. | $18.42 | 2025 | Livmarli |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $17.52 | 2023 | Ultomiris |
| Novo Nordisk INC | $11.23 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deena Kapadia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.